Just the biosimilars and/or reference products the payer wants to cover

Payer preferences on biosimilars often mean that health care providers must stock multiple biosimilar brands at high expense, adding complexity to the treatment process. In 

, legislators have introduced the first state legislation to require across-the-board coverage of biosimilars. “The change would give all patients access to the most affordable and effective version of their medication without compromising safety standards,” according to a statement from Representative Jennifer Schultz (D, Duluth) and Senator Carla Nelson (R, Rochester). Minnesota would follow up on the law, if enacted, to track effects on biosimilar and reference drug pricing.

Polls

News

Policy

Business & Practice

Coverage policies for biosimilars in the health care industry are the source of much angst.

Poll: How Much Discretion Should Payers Have Over Biosimilar Coverage?